Member Info for B2HS2L

Soder
· Group gross margin before exceptional items is expected to be in the region of 70% ;o)

Before reading the RNS I searched for TATA. :o(

https://www.linkedin.com/in/bryan-close-48782146/
I'm liking the Recommendations. - For me he was headhunted.

Ajan was COO and CTO.

Now Paul Oladimeji has the new equivalent of the old CTO position, and Bryan Close has the COO role, a very big improvement thanks DA.
++++
Ha Ha - DA did have a 100 day review period!

Seems I posted a corrupt link. - I'll try again:
https://www.linkedin.com/posts/jim-wicks-07228ba_productionmanager-seniorscientist-workingculture-activity-6888842604708982784-z8hS/

In the photo's of the Medlab 2022 stall today, I have not yet seen a CO-Prep cabinet.
Anyone else have a link that contains one please?

Hi neil,
Vito has liked two recent vacancies for YouSeq.
Of the 50 liking this link, twelve are from Novacyt, and one is from IT-IS.

https://www.linkedin.com/posts/jim-wicks-07228ba_production manager-seniorscientist-workingculture-activity-6888842604708982784-z8hS/

Jim Wicks (and a few other YouSeq directors) were working at Primerdesign at the time of AIM launch, but left to launch You Seq. Ties seem to be strengthening with time not diminishing.

Kaeren, the coffee table is in an interview suite, - we are going to get an interview.
Well, - I thought it was a good rumour to start.

Wilson, - If it were me I'd prefer to manufacture cheaply in Asia.
RNS 30.09 states "Novacyt has codeveloped CO-Prep™, an instrument for sample handling automation."
So I assume IT-IS provided the specification etc, and as the RNS's mention development, but not manufacture, I assume a subcontractor has that responsibility.
JM2c

It's a possibility that £100m will be exceeded due to lively sales reported last quarter by others, but we need to know if the products are limited by manufacturing constraint.
IMO if constrained, we can't improve revenue.
Is the co-prep product a dead duck as the manufacturer cannot deliver? - I'd be surprised if IT-IS manufactured it, but that's the kind of issue I was thinking of.

DRB, interested in your FY 21 H2 assumptions.
I cannot see where you are ramping anything! - Laughing out loud.

1
Q In the FY20 accounts, is there evidence that we created and delivered in H1 2021 projects (such as for instance), a bespoke respiratory panel (RNS'd thus: Molecular respiratory panel ready for US market Mon, 7th Oct 2019).

GM later advised that the success of our first to market single gene Covid-19 assay had stimulated a lot of interest in this bespoke design / development service which was, pre-Covid, one of our mainstays.
This project and others like it would not now be considered worthy of a separate RNS, but later larger projects might be evidenced in the 2021 H1 financials.

2
Cash at bank has always for me been like a vehicle MOT certificate, valid for the day it was issued.
It was planned to invest much into developing a nominaly 10 person direct sales team in USA. That might have happened and if it did that would require significant cash, if it didn't we haven't had that outlay.
We stated we would be launching many new projects within the next 12 months, so R&D for that is considerable.
We hired more people, and I would venture that the rate at which new staff are being hired is reducing compared to pre 18.10.2021. Salary bill is higher now than in previous 6 monthly periods.

3
How are we producing the sales we generate?
Is there more subcontract manufacture now, or have we acquired more facilities with which to produce ourselves?
Are we still using Chartwell to assist with making sure we cannot produce the goods faster or cheaper, streamlining our manufacturing capability to combat the increase in orders for a more successful sales / marketing team now DA has lit a fire beneath them?

2 and 3 for me means we have no idea what Cash at Bank is now, nor have we really for the last 6 months.

We have always been good at delivering high margins, and there is more competition around now than ever for all our products.
For ma I think we may still be achieving similar margins with a sales and marketing wiz at the helm. - Lets see.

Maria Van Kerkhove

https://twitter.com/mvankerkhove/status/1484601816759377922?s=10

John -
How would PE's know anything but the allegations printed. Without PE, there would be no allegations.
The hermits in Southampton and Camberley are not willing to discuss anything with PI's, and there are no II's.

Let's start with the end of January report, listen to management explaining how the numbers were generated, and perhaps after they have refused to say more on the dispute, we will hear mention of Private Eye. - I wouldn't bet on it however.

PI's definitely deserve to share an Allmond video, but IMO that's not on offer.

Ha ha!! - Don't tell Rishi 'til he's in a good mood ;o)

EXMEX, - October 2021
40 community diagnostic centres launching across England

https://www.gov.uk/government/news/40-community-diagnostic-centres-launching-across-england

This document states where the 40 centres will be.
A lot of great equipment being planned to put in the centres.
It does not mention PCR instruments, but it doesn't mean PCR instruments won't feature.

- a slug looked similar in comparison.

https://www.youtube.com/watch?v=msFwJ5xpg_g&t=2s

Start at 00:50.

Imagine Bezos is DA.

Assume Novacyt is the company that has been selling all the tests they can make, and that it's likely to continue.

00:50 - 'Your stock went from $100 to $6'.

Listen to DA's comments about falling sp and rising company metrics.

Wall Street kept saying 'where's the profit's', - DA was saying

'I don't really care what you think' (DA has not been prepared to say anything).

+++

This is similar to what's happening now.

We know we can sell PCR tests at a good margin, but nobody in Novacyt is publicising that fact, which affects the sp negatively.

Bezos was pleased his stock rose again.

Our turn comes at the end of January, when financials have to be made available, and plans should be made public.

OK the first bit is mandatory, the second bit ain't.

I recall KT,-
The point I'm making is that with a little more info, a lot more of the bigger picture comes into focus.

Hi Wilson,

I'd want to know if (for instance) GSK or AZN or both were manufacturing some of our tests, because they were among the few with large enough manufacturing capacity available to accept our regular orders.
No contract, because a contract would have to be announced, - it would move the sp, and that's not in keeping with managements present mode of operation.

Oriens, -
Just as concerning is that we have no idea the amount of tests being manufactured and by whom.
We have no idea what our manufacturing capacity is, or with whom we have a partnership.
Are they in UK/USA/Europe/China.
DA has a lot to discuss should he choose to.
Many new products due soon, - who's contracted to make them?

Hopefully they have given further thought to the number of Covid-19 Rapid Antigen tests per day likely to be required versus tests per day produced and available from Aldi.